Omnicom, WPP big winners in Bayer agency consolidation

Share this article:

Bayer announced today that it will split global advertising duties between Omnicom and WPP, a consolidation process set to be completed over the next two years.

Account duties at WPP will be shared between Ogilvy & Mather and JWT. At Omnicom, BBDO Worldwide and CDM will serve as lead agencies, according to an emailed statement from Bayer.

The consolidation will affect around 50 of Bayer's healthcare brands, including all major global, regional and launch brands. On the media buying and planning side, Bayer will consolidate all global accounts outside of the US with WPP's GroupM (which includes Maxus, Mediacom, Mediaedge:cia and Mindshare). Media assignments in the US were not affected; Bayer consolidated US media with Interpublic Group's Initiative agency last November.

Bayer Healthcare CEO Arthur Higgens said in the statement that Bayer hopes the consolidation will save the company as much as 10% in expenditures. Advertising Age put the total value of Bayer's healthcare advertising account at $850 million.

Bayer's Healthcare business, which includes pharmaceuticals, OTC drugs, animal health products and other consumer goods, had sales of just over $16 billion for the first nine months of 2009, according to third quarter reports. Despite some friction with DDMAC last year, Bayer's blockbuster birth control pill Yaz remains the company's best-selling pharmaceutical, at $1.3 billion for the first nine months of 2009.

Other top-selling pharmaceuticals for Bayer (for the first nine months of 2009) include the specialty drugs Betaseron ($1.2 billion), Kogenate ($930 million) and Nexavar ($608 million), as well as Adalat ($647 million), a heart drug, and Mirena ($502 million), an IUD for birth control.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...